Volume | 445,306 |
|
|||||
News | - | ||||||
Day High | 4.76 | Low High |
|||||
Day Low | 4.63 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Inozyme Pharma Inc | INZY | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.73 | 4.63 | 4.76 | 4.70 | 4.73 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,596 | 445,306 | $ 4.68 | $ 2,086,168 | - | 2.689 - 7.795 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:48:56 | 9 | $ 4.70 | USD |
Inozyme Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
290.33M | 61.77M | - | 0 | -71.17M | -1.15 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Inozyme Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INZY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.59 | 4.82 | 4.57 | 4.67 | 280,023 | 0.11 | 2.40% |
1 Month | 4.43 | 4.90 | 4.18 | 4.55 | 447,156 | 0.27 | 6.09% |
3 Months | 6.30 | 7.795 | 4.18 | 5.71 | 680,982 | -1.60 | -25.40% |
6 Months | 3.84 | 7.795 | 3.48 | 5.28 | 551,655 | 0.86 | 22.40% |
1 Year | 6.37 | 7.795 | 2.689 | 5.07 | 568,709 | -1.67 | -26.22% |
3 Years | 16.40 | 19.58 | 0.991 | 4.60 | 414,976 | -11.70 | -71.34% |
5 Years | 17.93 | 31.6499 | 0.991 | 5.35 | 339,374 | -13.23 | -73.79% |
Inozyme Pharma Description
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. |